Items Tagged ‘gefitinib’

September 23rd, 2015

Iressa® Approved as Initial Therapy for Lung Cancer

By

The targeted agent Iressa (gefitinib) has been approved by the U.S. Food and Drug Administration (FDA) as initial therapy in the treatment of patients with advanced lung cancer. Specifically, Iressa was approved as initial therapy for the treatment of patients with advanced non-small cell lung cancer (NSCLC) with specific mutations within the EGFR pathway. The […]

View full entry

Tags: advanced lung cancer, EGFR mutations, EGFR RGQ PCR Kit, FDA approval, gefitinib, iressa, Lung Cancer - Non-Small Cell, News, nsclc, Stages IIIB-IV Lung Cancer - Non-Small Cell


July 20th, 2015

FDA Approves Iressa for Treatment of Patients with Metastatic Non Small Cell Lung Cancer

By

The U. S. Food and Drug Administration approved IRESSA (gefitinib) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test. Gefitinib is being approved concurrently with a labeling expansion of […]

View full entry

Tags: FDA approval, gefitinib, Lung Cancer - Non-Small Cell, metastatic non-small cell lung cancer, News, nsclc, Stages IIIB-IV Lung Cancer - Non-Small Cell